<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648839</url>
  </required_header>
  <id_info>
    <org_study_id>D3250R00079</org_study_id>
    <nct_id>NCT04648839</nct_id>
  </id_info>
  <brief_title>Observational Retrospective Study on Clinical Outcomes of Patients Receiving Benralizumab in Spain.</brief_title>
  <acronym>ORBE-II</acronym>
  <official_title>Observational Retrospective Study to Characterise and Assess Clinical Outcomes of Patients Receiving Benralizumab After Marketing Approval in Spain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To describe the demographic and baseline characteristics in patients with severe&#xD;
           eosinophilic asthma in Spain who received at least one dose of Benralizumab, after its&#xD;
           marketing authorization&#xD;
&#xD;
        2. To describe background treatment patterns of severe eosinophilic asthma patients at&#xD;
           baseline and after the index date (benralizumab initiation)&#xD;
&#xD;
      This is a descriptive, observational, multi-centre, longitudinal, retrospective cohort study&#xD;
      in adults patients (≥18 years) with severe asthma (maintenance treatment with high dose&#xD;
      inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype,&#xD;
      who, at the discretion of the physician, received benralizumab accordingly to the clinical&#xD;
      practice, in the period after the marketing authorization of benralizumab in Spain, on&#xD;
      January 1st 2019.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Actual">July 16, 2021</completion_date>
  <primary_completion_date type="Actual">July 16, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age</measure>
    <time_frame>Up to 12 months (Baseline period)</time_frame>
    <description>Specifically, at the time of taking the first dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gender</measure>
    <time_frame>Up to 12 months (Baseline period)</time_frame>
    <description>Specifically, at the time of taking the first dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking Habits</measure>
    <time_frame>Up to 12 months (Baseline period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Age at athma diagnosis</measure>
    <time_frame>Up to 12 months (Baseline period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood eosinophils count</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total IgE</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with positive Prick test</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FeNo</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function (FEV1 and FVC)</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ACT (or ACQ) score</measure>
    <time_frame>Baseline period</time_frame>
    <description>Asthma Control Test (ACT), the scores range from 5 to 25, with higher scores reflecting greater asthma control.&#xD;
Asthma Control Questionnaire (ACQ), the total score range between 0 (well controlled asthma) and 6 (extremely poorly controlled)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AQLQ score</measure>
    <time_frame>Baseline period</time_frame>
    <description>Asthma Quality of Life Questionnaire (AQLQ), it scores from 1 (minimum) to 7 (maximum) where the higher the score, the better the quality of life is</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe asthma exacerbations</measure>
    <time_frame>In the previous 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Key comorbidities</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OCS-related comorbidities</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant asthma medications</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician office visits</measure>
    <time_frame>Baseline period</time_frame>
    <description>Split by primary care and specialist (asthma related)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emergency room visits</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalisations</measure>
    <time_frame>Baseline period</time_frame>
    <description>Number and duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of laboratory tests per patient</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of conventional radiology procedures per patient</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of diagnostic/therapeutic tests per patient</measure>
    <time_frame>Baseline period</time_frame>
    <description>Asthma related only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of spirometries per patient</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of allergy tests per patient</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of computed axial tomographies per patient</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of magnetic resonance imaging procedures per patient</measure>
    <time_frame>Baseline period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma treatment</measure>
    <time_frame>Up to 24 months (study duration)</time_frame>
    <description>Including previous biologic treatment, type of treatment and reasons for discontinuation or switching</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">221</enrollment>
  <condition>Severe Asthma</condition>
  <arm_group>
    <arm_group_label>Benralizumab</arm_group_label>
    <description>Patients that received at least one dose of benralizumab according to routine clinical practice</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The target population will be all patients with severe eosinophilic asthma (those requiring&#xD;
        stable treatment with high doses of inhaled corticosteroids and a long-acting agonist β2 ±&#xD;
        additional asthma controller), who received at least one dose of benralizumab according to&#xD;
        routine clinical practice, after marketing approval on January 1st, 2019. The targeted&#xD;
        patients need to have available medical record of 12 months prior to index date.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (age ≥18 years)&#xD;
&#xD;
          -  Diagnosis of severe eosinophilic asthma requiring stable treatment of high doses of&#xD;
             inhaled corticosteroids and a long-acting agonist β2 ± additional asthma controller.&#xD;
&#xD;
          -  Patients with at least 12-month data available before index date (starting&#xD;
             benralizumab treatment)&#xD;
&#xD;
          -  Patients with at least 3-month electronic medical records data available from first&#xD;
             benralizumab dose (&quot;index date&quot;)&#xD;
&#xD;
          -  Informed consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received benralizumab in a clinicaltrial, during the observation period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marbella</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

